HUTCHMED (China) Limited announced that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online. Details of the presentations are as follows: Efficacy and Safety of The Syk Inhibitor Sovleplenib Renchi Yang #S316 (HMPL-523) in Adult Patients with Primary Immune Institute of Hematology and Blood Diseases Oral Presentation (Platelet disorders in the Thrombocytopenia in China (ESLIM-01): A Randomized, Hospital, Chinese Academy of Medical Sciences, spotlight: Clinical and translational) Double-Blind, Placebo-Controlled Phase 3 Study Tianjin, China, China, Phase 2 Part of the Study Tianjin, China, 12:00 - 12:15 CEST, Hall Mallo, Xiaofan Liu #P1629. Patients by Prior Lines of Therapy: Subgroup Institute of Hematology and blood Diseases Poster Session, June 14, 2024, Placebo- Controlled Phase 3 Study (ESLIM-01) Tianjin, China, Seng Mei #P1631.

Pts with Prior TPO/TPO-RA Treatment: Subgroup Union Hospital, Tongji Medical College, Poster Session analysis of a Multicenter, Randomized, Double-Blind, Hospital, Chinese Academy of medical Sciences, Sunday, June 16, 2024. Phase 2 Part of the Study: Tianjin, China, China. Safety and Efficacy of Syk Inhibitor Sovlenib in Paolo Strati #P1102.

Heavily Pre-Treated Hodgkin Lymphoma Patients The University of Texas MD Anderson Cancer Poster Session Center, Houston, U.S. Friday, June 14, 2024. Myeloid Hematological Malignancies Harboring IDH1 Peking University People's Hospital, Beijing, Poster Session and/or IDH2 Mutations: Final result of Dose China. Expansion in Phase 1 Study of HMPL-306 in Patients with Advanced Pau Montesinos #P549.

Acute Myeloid Leukemia with Isocitrate Dehydrogenase Hospital Universitario La Fe, Valencia, Spain Poster Session (IDH) Mutations: Preliminary Results of the Dose Friday, June 14, 2024; Escalation Cohorts Phase II Study of EZH2 Inhibitor Tazemetostat plus Mingci Cai #P2080. Amdizalisib, a PI3K Inhibitor, in Patients with Ruijin Hospital affiliated to Shanghai Jiao e-Poster Presentation Relapsed/Refractory Lymphomas Tong University School of Medicine, Shanghai, Friday, June 14, 2024, June 14, 2024.